Kinomica’s LC-MS/MS Quantitative Phosphoproteomics methodology has been developed on cutting edge instrumentation. Initially developed on the LTQ-Orbitrap platform in 2008, it has been continually improved and enhanced as the Mass Spectrometry instruments have evolved to higher and faster performance levels.
The KScan® platform takes the LC-MS/MS raw data as its input; the minimum performance standard is validated on the Q-Exactive Plus. Data can be used from other types of Mass Spectrometer, meeting an equivalent-or-better level of performance.
Reliable and Reproducible data, across large batches, is critical to KScan®’s success. To ensure liquid handling is accurate, Kinomica employ the Bravo AssayMAP for the phosphoenrichment part of the method.
The Solution: KScan®
KScan®: A next generation biomarker and molecular diagnostics platform
What is KScan®?
A patented database of kinase substrate relationships
Patented algorithms to determine which kinases are enriched
Kinase Activity Leader Board - K-Score
Patented Method for systematic identification of regulatory protein kinases (K-Score)
Significance of KScan®
Take a look at our library of publications and presentations that cover the topic of our LC-MS/MS technology in more detail.
Find out more about Kinomica’s powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods
Learn more about Kinomica, our team and our technology through our in-depth blog content. We’ll also let you know what events we are attending as well.
Talk to our Experts
To find out more about the technology behind Kinomica’s advanced bioinformatics and phosphoproteomics analytical methods, talk to our experts.
If you have any questions or need any further information, then please contact the Kinomica team – we are more than happy to help.
“We can help scientists to understand more accurately where their drugs can have the most efficacious impact, reducing costs and speeding development, and we can help clinicians identify which drug will work most effectively in a patient target group”
Anthony Sullivan, Business Development Director